Antibodies to human carcinoma antigen
AssigneeEpigen, Inc.
InventorsJohn F. Codington, Svein Haavik
Life of this patent
Estimating the term…
Loading patent…
AssigneeEpigen, Inc.
InventorsJohn F. Codington, Svein Haavik
Estimating the term…
A glycoprotein antigen which is generally characteristic of human carcinomas, regardless of the tissue associated with the carcinoma--human carcinoma antigen (HCA)--and which is generally not present on normal human cells. Immunodeterminant-containing fragments of HCA substantially separated from elements of HCA's naturally occurring environment are also disclosed. HCA is generally characterized by: a) a molecular weight in excess of 750,000; b) carbohydrate moieties characteristic of mucin-type glycoproteins and comprising a relatively high proportion of sialic acid, galactose, and N-acetylgalactosamine residues (e.g., at least 50% of the carbohydrate residues are sialic acid, galactose, or N-acetylgalactosamine residues); c) an isoelectric point below pH 3.0; d) presence generally on human carcinoma cells; e) absence generally from non-transformed human cells; f) at least one immunodeterminant that specifically reacts with anti-murine epiglycanin antibody AE3; and g) general insolubility in aqueous fluids (e.g., a phosphoric acid or an HCl solution) below pH 2.0 Also disclosed are antibodies to HCA, immunoassays for HCA, in vivo imaging using HCA-binding antibodies and therapeutics using HCA or anti-idiotypic HCA antibodies.
Antibody specific for human carcinoma antigen (HCA), said antibody being less reactive with mouse epiglycanin than with HCA.
Antibody that binds HCA, wherein said antibody is produced by administering to a mammal an immunogen selected from the group consisting of:
Idiotypic antibody that binds HCA-binding antibody.
Dependencies are inferred from the claim text.